The ZENITH20-2 trial treated 90 patients with HER2-mutated NSCLC with poziotinib, showing moderate efficacy (ORR of 27.8% and mPFS of 5.5 months). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.